Value of Uric Acid as Early Predictor of Lupus Nephritis
1 other identifier
observational
100
1 country
1
Brief Summary
The aim of the present work is to determine the role of uric acid as a predictor and prognostic factor in the development of lupus nephritis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 29, 2022
CompletedFirst Posted
Study publicly available on registry
June 2, 2022
CompletedStudy Start
First participant enrolled
June 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 12, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 25, 2023
CompletedJune 2, 2022
May 1, 2022
1.1 years
May 29, 2022
May 29, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Value of uric acid as early predictor of lupus nephritis in Assiut University hospital
The aim of the present work is to determine the role of uric acid as a predictor and prognostic factor in the development of lupus nephritis. The aim of the present work is to determine the role of uric acid as a predictor and prognostic factor in the development of lupus nephritis.
1 year
Interventions
Serum uric acid level
Eligibility Criteria
All patients fulfilled the European League Against Rheumatism (EULAR) and the American college of rheumatology (ACR)
You may qualify if:
- All patients fulfilled the European League Against Rheumatism (EULAR) and the American college of rheumatology (ACR)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
assuit University
Asyut, Egypt
Related Publications (13)
Yuan W, DiMartino SJ, Redecha PB, Ivashkiv LB, Salmon JE. Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes. Arthritis Rheum. 2011 Jan;63(1):212-8. doi: 10.1002/art.30083.
PMID: 20954190BACKGROUNDBorchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME. Lupus nephritis: a critical review. Autoimmun Rev. 2012 Dec;12(2):174-94. doi: 10.1016/j.autrev.2012.08.018. Epub 2012 Sep 8.
PMID: 22982174BACKGROUNDZubair A, Frieri M. Lupus nephritis: review of the literature. Curr Allergy Asthma Rep. 2013 Dec;13(6):580-6. doi: 10.1007/s11882-013-0394-4.
PMID: 24234325BACKGROUNDKoutsokeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov. 2014 Mar;13(3):173-4. doi: 10.1038/nrd4227. Epub 2014 Feb 14. No abstract available.
PMID: 24525782BACKGROUNDCameron JS, Hicks J. The introduction of renal biopsy into nephrology from 1901 to 1961: a paradigm of the forming of nephrology by technology. Am J Nephrol. 1997;17(3-4):347-58. doi: 10.1159/000169122.
PMID: 9189255BACKGROUNDXie T, Chen M, Tang X, Yin H, Wang X, Li G, Li J, Zuo X, Zhang W. Hyperuricemia is an independent risk factor for renal pathological damage and poor prognosis in lupus nephritis patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016 Oct 28;41(10):1052-1057. doi: 10.11817/j.issn.1672-7347.2016.10.007.
PMID: 27807327BACKGROUNDKang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002 Dec;13(12):2888-97. doi: 10.1097/01.asn.0000034910.58454.fd.
PMID: 12444207BACKGROUNDDesideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, Punzi L, Borghi C. Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci. 2014;18(9):1295-306.
PMID: 24867507BACKGROUNDMazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001 Nov;38(5):1101-6. doi: 10.1161/hy1101.092839.
PMID: 11711505BACKGROUNDLiu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol (Oxf). 2015 Oct;83(4):475-82. doi: 10.1111/cen.12673. Epub 2014 Dec 29.
PMID: 25400252BACKGROUNDCheng GY, Liu DW, Zhang N, Tang L, Zhao ZZ, Liu ZS. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up. Clin Nephrol. 2013 Jul;80(1):40-6. doi: 10.5414/CN107813.
PMID: 23391320BACKGROUNDLi C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013 Mar;25(2):210-6. doi: 10.1097/BOR.0b013e32835d951e.
PMID: 23370374BACKGROUNDSertoglu E. Serum uric acid: an independent predictive marker for coronary artery disease. Clin Rheumatol. 2015 Sep;34(9):1659. doi: 10.1007/s10067-015-2919-9. Epub 2015 Mar 22. No abstract available.
PMID: 25796387BACKGROUND
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principle investigator
Study Record Dates
First Submitted
May 29, 2022
First Posted
June 2, 2022
Study Start
June 15, 2022
Primary Completion
July 12, 2023
Study Completion
August 25, 2023
Last Updated
June 2, 2022
Record last verified: 2022-05